WHO recommends two new drugs to combat COVID-19 infection

0

The World Health Organization (WHO) recommended two new drugs to combat COVID-19 infections.

The first new drug that is recommended for critical COVID-19 cases is baricitinib, an oral drug that suppresses the immune system when overstimulated. 

The WHO recommends baricitinib is given with corticosteroids.

The second drug which should be used for mild cases where a person has a high chance of hospitalization is sotrovimab, a monoclonal antibody drug. 

This should be given to individuals who are unvaccinated, older, have a compromised immune system or are obese, according to the WHO. 

“The extent to which these medicines will save lives depends on how widely available and affordable they will be,” the WHO said in its statement. 

The recommendations come as concerns arise that existing COVID-19 treatments will not be effective against the omicron variant.

The two drugs were also invited on Friday to go through the WHO’s Prequalification Unit, which “assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.”

The WHO recommended the two drugs after evaluating evidence gathered in seven trials examining 4,000 mild, severe and critical COVID-19 cases.

The Food and Drug Administration has already approved baricitinib and sotrovimab for emergency use. 

The WHO has recommended against ruxolitinib and tofacitinib due to their uncertain effects.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health & Fitness News Click Here 

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment